Concepedia

Publication | Closed Access

Maternal Toxicity With Continuous Nevirapine in Pregnancy

DOI

144

Citations

6

References

2004

Year

Jane Hitti, Lisa M. Frenkel, Alice Stek, Sharon Nachman, David A. Baker, Adolfo González-García, Arthur J. Provisor, Edwin Thorpe, Mary E. Paul, Marc Foca,
JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

Continuous nevirapine may be associated with increased toxicity among HIV-1-infected pregnant women with CD4 cell counts greater than 250 cells/microL, as has been observed in non-pregnant women.

References

YearCitations

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

Laura Guay, Philippa Musoke, Thomas R. Fleming,

The Lancet

1999

1.6K

Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission<SUBTITLE>A Randomized Trial</SUBTITLE>

Alejandro Dorenbaum

JAMA

2002

370

A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Mother‐to‐Child Transmission of Human Immunodeficiency Virus Type 1

Dhayendre Moodley, Jagidesa Moodley, Hoosen Coovadia,

The Journal of Infectious Diseases

2003

344

A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

Jerry O. Stern, Patrick Robinson, James E. Love,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2003

237

Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus*1

Eric Knudtson

Obstetrics and Gynecology

2003

40

Fatal liver failure associated with Nevirapine in a pregnant HIV patient: The first reported case

Philippe Langlet, Marie-Paule Guillaume, Jacques Devriendt,

Gastroenterology

2000

11

Page 1